Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 13/20 | 0.56 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.53 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL727185 | 0.85 | CYP1A2 (0.62) | TBXAS1CYP11B1CYP11B2HRH4HRH3 | |
| SCHEMBL29995759 | 0.83 | CYP11B1 (0.65) | TBXAS1CYP11B1CYP11B2HRH4HRH3 | |
| SCHEMBL177863 | 0.83 | CYP11B1 (0.65) | TBXAS1CYP11B1CYP11B2HRH4HRH3 | |
| SCHEMBL8307942 | 0.82 | CYP11B1 (0.47) | TBXAS1CYP11B1CYP11B2HRH4HRH3 | |
| Hydrochloric Acid SCHEMBL10665044 | 0.81 | TBXAS1 (0.64) | TBXAS1CYP11B1CYP11B2HRH4HRH3 | |
| Ammonia Solution, Strong SCHEMBL5999508 | 0.81 | CYP11B1 (0.62) | TBXAS1CYP11B1CYP11B2HRH4HRH3 | |
| SCHEMBL3758352 | 0.80 | TBXAS1 (0.56) | TBXAS1CYP11B1CYP11B2HRH4HRH3 | |
| SCHEMBL4248371 | 0.80 | TBXAS1 (0.60) | TBXAS1CYP11B1CYP11B2 | |
| SCHEMBL6649631 | 0.80 | TBXAS1 (0.56) | TBXAS1CYP11B1CYP11B2HRH4HRH3 | |
| SCHEMBL5780182 | 0.80 | ALDH1A1 (0.59) | TBXAS1CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116854697-A | Organic small molecule based on diindolylcarbazole structure and application thereof | 深圳大学 | 2023-10-10 | — | — | CN | disclosed |
| CN-102066337-A | 5-hydroxypyrimidine-4-carboxamide compounds | DAIICHI SANKYO CO LTD | 2011-05-18 | — | — | CN | disclosed |
| US-20110112103-A1 | 5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112103-A1 | 5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE COMPOUND | EPOR, CBR1, CBR3 | TBXAS1 1732/4885CYP11B1 104/4885CYP11B2 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.